Gene
LEPR
LEPR is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (1), Assay-provider ledger (10), Trial mentions (46), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention LEPR. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 6 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 2 of 8,738 | 0.02% | not measured | |
| 2025 | 3 of 8,875 | 0.03% | not measured | |
| 2024 | 2 of 8,597 | 0.02% | not measured | |
| 2023 | 3 of 8,275 | 0.04% | 10 of 11,460 | 0.09% |
| 2022 | 5 of 8,285 | 0.06% | 15 of 13,598 | 0.11% |
| 2021 | 5 of 8,692 | 0.06% | 21 of 15,045 | 0.14% |
| 2020 | 1 of 7,640 | 0.01% | 18 of 14,459 | 0.12% |
| 2019 | 3 of 7,300 | 0.04% | 15 of 12,159 | 0.12% |
| 2018 | 4 of 6,927 | 0.06% | 24 of 11,854 | 0.20% |
| 2017 | 2 of 6,558 | 0.03% | 27 of 11,595 | 0.23% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (1)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| POMC/PCSK1/LEPR CDx Panel | LEPR | PreventionGenetics, LLC | Obesity | 2022-01-21 |
Assay-provider ledger (10)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| BioVendor Research and Diagnostic Products | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | June 21, 2018 |
| Cardiovascular Engineering, Inc | Unclassified | No clinical or analytical validation recorded for this pair | 1 | June 21, 2018 |
| R & D Systems | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | June 21, 2018 |
| BioVendor Research and Diagnostic Products, Candler, NC | Unclassified | No clinical or analytical validation recorded for this pair | 1 | February 29, 2016 |
| R & D Systems, Inc., Minneapolis, MN | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | February 29, 2016 |
Showing 5 of 10 assay-provider companies.
Trial mentions (46)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT03479437 | Trial eligibility (AACT) |
| NCT00784147 | Trial eligibility (AACT) |
| NCT06799338 | Trial eligibility (AACT) |
| NCT07393360 | Trial eligibility (AACT) |
| NCT05774756 | Trial eligibility (AACT) |
Showing 5 of 46 trial mentions.
Target-disease associations (857)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 3-methylcrotonyl-CoA carboxylase deficiency | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 3-methylglutaconic aciduria type 1 | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
Showing 5 of 857 associations.
Vendor sourcing (142)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.035%). Functional studies provide strong eviden... | View ClinVar record SCV002521388.1 |
| AN2 Therapeutics, Inc. | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Male or female patients who are 18 years of age or older. 2. Willing and able to provide written informed consent. 3. Patients with a diagnosis of trea... | View trial NCT05327803 |
| AN2 Therapeutics, Inc. | Trial sponsor | Mentioned in trial textTrial free-text mention | OBR | View trial NCT05327803 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1651A>C (p.I551L) alteration is located in exon 12 (coding exon 10) of the LEPR gene. This alteration results from a A to C substitution at nucleotide ... | View ClinVar record SCV003536206.2 |
| Azienda Ospedaliero Universitaria Maggiore della Carita | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Male or female participants aged 0 to 99 years. * Diagnosis of leptin receptor deficiency (LEPRD) or genetically determined leptin deficiency associated... | View trial NCT07833592 |
Showing 5 of 142 sourcing records.
Trial-cited literature (295)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial. | The lancet. Diabetes & endocrinology | 2025 | 37 |
| Three-protein signature is associated with baseline and persistently elevated or recurrent depressive symptoms in individuals with recent-onset diabetes. | BMJ open diabetes research & care | 2025 | 2 |
| The Impact of Glucomannan, Inulin, and Psyllium Supplementation (Soloways<sup>TM</sup>) on Weight Loss in Adults with FTO, LEP, LEPR, and MC4R Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial. | Nutrients | 2024 | 10 |
| Monoallelic pathogenic variants in LEPR do not cause obesity. | American journal of human genetics | 2024 | 7 |
| The Association of Plasma Leptin, Soluble Leptin Receptor and Total and High-Molecular Weight Adiponectin With the Risk of Perioperative Neurocognitive Disorders. | The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry | 2024 | 5 |
Showing 5 of 295 papers.
Protein variant mentions (32)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.C352F | 1 | 2015 | PMID 25741868 |
| p.E06A | 1 | 2020 | PMID 32528467 |
| p.I1085V | 1 | 2015 | PMID 25741868 |
| p.I28V | 1 | 2005 | PMID 15919835 |
| p.I551N | 1 | 2016 | PMID 26467025 |
Showing 5 of 32 variants.
Literature-extracted relations (53)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| METFORMIN | Chemical | negative_correlate |
Metformin inhibits leptin-induced growth and migration of glioblastoma cells. | 2012 |
| Dopamine | Chemical | associate |
Leptin acts via leptin receptor-expressing lateral hypothalamic neurons to modulate the mesolimbic dopamine system and suppress feeding. | 2009 |
| Risperidone | Chemical | associate |
Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. | 2007 |
| Anhydrous glucose | Chemical | associate |
Genetic variation in leptin receptor gene is associated with type 2 diabetes and body weight: The Finnish Diabetes Prevention Study. | 2005 |
| Anhydrous glucose | Chemical | associate |
Leptin and leptin receptor gene polymorphisms and changes in glucose homeostasis in response to regular exercise in nondiabetic individuals: the HERITAGE family study. | 2004 |
Showing 5 of 53 relation assertions.
Organizations publishing (272)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 9 | 2010 to 2018 |
| University of Pennsylvania | Academic | 8 | 2013 to 2021 |
| Harvard Medical School | Academic | 6 | 2009 to 2022 |
| University of North Carolina System | Academic | 6 | 2010 to 2022 |
| Assistance Publique – Hôpitaux de Paris | Hospital | 5 | 2018 to 2024 |
Showing 5 of 272 organizations.
Where LEPR appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
815 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects, actionable biomarkers, and human sample screening reference.